BioMed Research International

Chemotherapy-Induced Nausea and Vomiting


Status
Published

1The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

2The Hong Kong Polytechnic University, Hong Kong

3Merck & Co Inc, Rahway, USA

4Azienda Ospedaliera S. Maria di Terni, Terni, Italy


Chemotherapy-Induced Nausea and Vomiting

Description

Chemotherapy-induced nausea and vomiting (CINV) continues to be an important problem for cancer patients receiving chemotherapy and is one of the most feared side effects of anticancer treatment. Inadequately controlled CINV could be associated with a significant negative impact on quality of life and can compromise treatment compliance. A number of antiemetic agents are available in the management of nausea and vomiting, including 5-HT3-receptor-antagonists, corticosteroids, NK-1-receptor-antagonists, and dopamine-receptor antagonists. Vomiting can be prevented in 70-80% of patients, whereas the control of nausea remains suboptimal. Serotonin is associated with the development of acute emesis. The pathophysiology of delayed emesis is more complex and less well understood. There are multiple mechanisms, including but not restricted to substance P that contributes in the development of delayed emesis.

We invite authors to submit original research and review articles on the topic of CINV. We are interested in articles that explore all aspects of CINV including basic mechanism and pathophysiology.

Potential topics include, but are not limited to:

  • Cellular mechanisms of the antiemetic action of 5HT3 receptor antagonist, NK1 receptor antagonists, dexamethasone, and related glucocorticoids against CINV
  • New 5HT3 antagonists and NK1 receptor antagonists agents (ramosetron, oral palonosetron, rolapitant, and netupitant)
  • Olanzapine in the treatment of CINV
  • Acute and delayed emesis associated with either highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC)
  • Radiation therapy-induced nausea and vomiting
  • Prevention of CINV on patients undergoing oral chemotherapy agents
  • CINV in multiple-day chemotherapy
  • CINV in patients undergoing bone marrow transplantation
  • Prevention of chemotherapy-induced nausea and vomiting (CINV) in children
  • Breakthrough and refractory CINV
  • Anticipatory CINV
  • Risk factors predicting chemotherapy-related nausea and vomiting
  • Antiemetic guidelines on CINV and guidelines implementation
  • Impact on quality of life of patients with CINV
  • Specific disease areas dealing with CINV in patients with lung cancer, breast cancer, colorectal cancer, gynecological cancers, and hematological malignancies

Articles

  • Special Issue
  • - Volume 2015
  • - Article ID 457326
  • - Editorial

Chemotherapy-Induced Nausea and Vomiting

Bernardo Leon Rapoport | Alexander Molasiotis | ... | Fausto Roila
  • Special Issue
  • - Volume 2015
  • - Article ID 309601
  • - Review Article

Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

Ana Lúcia Costa | Catarina Abreu | ... | Luís Costa
  • Special Issue
  • - Volume 2015
  • - Article ID 595894
  • - Review Article

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari
  • Special Issue
  • - Volume 2015
  • - Article ID 495704
  • - Review Article

Biological and Pharmacological Aspects of the NK1-Receptor

Susana Garcia-Recio | Pedro Gascón
  • Special Issue
  • - Volume 2015
  • - Article ID 523601
  • - Clinical Study

A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting

Ka-Rham Kim | Gaeun Kang | ... | Sang-Hee Cho
  • Special Issue
  • - Volume 2015
  • - Article ID 943618
  • - Review Article

Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy

Praveen Ranganath | Lawrence Einhorn | Costantine Albany
  • Special Issue
  • - Volume 2015
  • - Article ID 893013
  • - Review Article

Prophylactic Management of Radiation-Induced Nausea and Vomiting

Petra Feyer | Franziska Jahn | Karin Jordan
  • Special Issue
  • - Volume 2015
  • - Article ID 956785
  • - Clinical Study

Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy

Masakazu Abe | Yuka Kasamatsu | ... | Yasuyuki Hirashima
  • Special Issue
  • - Volume 2015
  • - Article ID 651879
  • - Review Article

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Paul J. Hesketh | Matti Aapro | ... | Hope Rugo
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision77 days
Acceptance to publication53 days
CiteScore2.410
Impact Factor2.197
 Submit